RESI Innovation Challenge
RESI on MaRS 2017 Innovation Challenge Companies
To add some friendly competition to the mix, the RESI Innovation Challenge invites all attendees to participate in a virtual investment contest. At the start of the day, each attendee will receive “RESI Cash” to allocate to the entrepreneurs whose technologies they expect will be most influential. The capital invested will be tallied up and the top three winners will receive prizes and be featured in our RESI newsletter recap that will go out to LSN’s 20,000 newsletter readership.
Whether you are an investor, an entrepreneur, or a service provider, make sure you check out the exhibit hall to meet with some of the top innovators in the field and invest your “RESI Cash.” We will see you there!
NOTE: Please fill out this application form as completely as possible. The application process takes approximately 15 minutes. Please copy and paste your application into a word file before hitting “Register” in case of technical problems during submission. If you don’t receive the confirmation email after submission, please send the word file to email@example.com. Your can download the file here: http://goo.gl/79Mwki. There is no fee to apply.
Also, please send additional materials such as your pitch deck and executive summary to firstname.lastname@example.org for us to review along with your application to the RESI Innovation Challenge.
MyndBlue is a digital health/ connected medical device that detects and monitors relapse/recurrence in Major Depressive Disorders and Chronic PTSD. The company is headquartered in Paris and has US office in Cambridge, MA. MyndBlue’s mission is to change the way mental health conditions are diagnosed through technology, data and design – to get patients the right care. Mental health conditions affect around 615 million people worldwide. MyndBlue’s remote monitoring platform allows for a patient to be monitored with a proprietary device to provide information to a clinician before a crisis.
Sexual dysfunction and urinary incontinence are both common side effects following prostate cancer surgery. Inadvertent nerve injury occurring during the surgery is believed to be one of the primary causes. Using nerve monitoring technology that has been the Standard of Care in multiple surgical procedures for over 20 years, the ProPep® Nerve Monitoring System brings the same instant and accurate information regarding nerve location and function to laparoscopic and robotic prostatectomy surgery for the first time ever. The ProPep® Nerve Monitoring System is the first FDA-cleared real-time nerve monitoring system for laparoscopic & robotic prostatectomy surgery. With over 2500 commercial cases completed this system is proven to help surgeons identify critical non-visible somatic nerves at risk during surgery, thereby allowing the surgeon to make more-informed decisions on how to spare these nerves, potentially minimizing nerve damage.